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The complexity and heterogeneity of tumours have hindered efforts to identify commonalities among
different cancers. Furthermore, because we have limited information on the prevalence and nature of
ubiquitous molecular events that occur in neoplasms, it is unfeasible to implement molecular-targeted
cancer screening and prevention. Here, we found that the FEAT protein is overexpressed in most human
cancers, but weakly expressed in normal tissues including the testis, brain, and liver. Transgenic mice that
ectopically expressed FEAT in the thymus, spleen, liver, and lung spontaneously developed invasive
malignant lymphoma (48%, 19/40) and lung-metastasizing liver cancer (hepatocellular carcinoma) (35%,
14/40) that models human hepatocarcinogenesis, indicating the FEAT protein potently drives
tumorigenesis in vivo. Gene expression profiling suggested that FEAT drives receptor tyrosine kinase and
hedgehog signalling pathways. These findings demonstrate that integrated efforts to identify FEAT-like
ubiquitous oncoproteins are useful and may provide promising approaches for cost-effective cancer
screening and prevention.
A
lthough our understanding of the molecular mechanisms of carcinogenesis has greatly improved, this
knowledge has not lead to the identification and development of effective tools for cancer screening and
prevention
1. Approximately 30–40% of all cancer deaths are preventable, and this estimation is based on
indirect measures that do not interfere with carcinogenesis, such as dietary modifications, lifestyle changes,
minimizing carcinogen exposure, and vaccination against oncogenic viruses
1. More advanced chemoprevention
measures such as tamoxifen, raloxifene, finasteride, and celecoxib
1 and the eradication of Helicobacter pylori are
only available to high-risk groups for particular cancers.
In order to reach the long-term goal of establishing molecular-targeted cancer screening and prevention, it is
important that we explore, characterize, and catalogue a distinct subclass of cancer genes
2 that are involved in
diverse cancers. However, the systematic approaches that have been used to identify cancer genes, such as
sequencing protein-coding exons
3–9, whole genome sequencing
10,11, and paired-end sequencing to comprehen-
sively identify somatic rearrangements
12, have only further emphasized the marked heterogeneity and complex-
ity of human neoplasms and have not successfully identified commonalities among cancers. Driver mutations
that contribute to the development of human cancers
13 are highly variable among different types of cancer and
among individual tumours of the same type. Thus, it is still unknown if there are oncogenic molecules that are
commonly altered in diverse cancers.
Thereisaccumulatingevidencethatcancershaveheterogeneouscombinationsofderegulatedcancergenes
13,14
and that signalling pathways rather than individual genes are the targets in tumorigenesis
15. Although some
canonicalsignallingpathwaysareuniversallyderegulatedincancers,differentcomponentsofthesepathwayscan
be affected in different tumours
3,5–9,15. The proteins that are commonly overexpressed in cancers are predomi-
nantly thought to reflect ‘‘peripheral’’ changes
2,15 that result from neoplastic phenotypes (i.e., augmented meta-
bolic and homeostatic processes such as glycolysis, macromolecular synthesis, and DNA replication)
16,17 and the
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18. Thus, these proteins have not been
considered as targets for cancer therapy and prevention. However,
this presumption has not been rigorously tested in vivo
19.
Inthepresentstudy,wefoundthatFEATprotein(faintexpression
in normal tissues, aberrant overexpression in tumours) is uniformly
overexpressed in a variety of human cancers. Remarkably, FEAT
transgenic mice indicated that FEAT potently drives tumorigenesis
invivo.ExpressionmicroarrayanalysessuggestedthatFEATinduces
oncogenicpathways.Thesignificanceofoverexpressedgenesincan-
cer is increasingly recognized as potential leads for a variety of dia-
gnostic and therapeutic approaches
6,7,20. Additional studies that
identify and characterize FEAT-like oncogenic proteins will hope-
fully advance molecular-targeted cancer screening and prevention.
Results
Biochemical purification of FEAT protein. Onanalyses of molecules
regulating nuclear apoptosis in a cell-free system
21,22,w en o t i c e dt h a t
the apoptosis-inducing activity was attenuated in the middle of active
fractions, concomitant with the appearance of two polypeptides with
apparent molecular masses of 74 and 66 kDa (Supplementary Fig. 1).
Thissuggestedthatapoptosisinhibitorswerecopurifiedwithapoptosis
inducers. Microsequencing revealed that the 74 kDa protein is a rat
homologueofhumanCGI-01protein
23thatisencodedbyMETTL13
(methyltransferaselike13)gene(alsoknownasKIAA0859).CGI-01,
renamed FEAT, contains two S-adenosylmethionine-binding motifs
(SAM-binding motifs) that are characteristic of methyltransferases
and related enzymes (see Fig.1f)
24, and the structure is well conserved
across species (Supplementary Fig. 2). Capture compounds mass
spectrometry using S-adenosylhomocysteine has detected the
Arabidopsis thaliana orthologue of FEAT (At2g31740)
25,
suggesting that FEAT can bind SAM. We did not detect protein
methyltransferase activity, spermidine/spermine synthase activity,
or ubiquinone synthase activity (Supplementary Fig. 3) in full-
length or truncated FEAT proteins (Supplementary Note). Further
Figure 1 | FEAT is a substrate for caspase-3. (a) Cleavage ofN-terminal Myc-tagged FEAT(myc-FEAT) inapoptotic cells. COS-7 cells expressing myc-
FEATweretreatedwith1mMstaurosporine(STS)fortheindicatedtimes.Lane5:cellspretreatedfor30 minwith100mMzVAD-fmk, abroadspectrum
caspase inhibitor. (b) In vitro transcribed/translated [
35S]-labelled FEAT was cleaved by purified caspase-3, but not by caspase-6. (c) Caspase-3 is mainly
responsible for FEAT cleavages. MCF-7 cells expressing myc-FEAT alone or together with procaspase-3 (1 casp-3) were treated with 1 mM STS for the
indicatedtimes.(d)Mutatingcaspase-3 cleavagesitesabrogates FEATcleavages. COS-7expressingwild-type(wt)or mutantmyc-FEAT weretreatedfor
6 h with 1 mM STS (lane 2 to 5). Immunoblots (a, c, d) were probed with an anti-Myc antibody. (e) Cleavage of endogenous FEAT in apoptotic cells.
Jurkat T cells preincubated for 1 h without or with 100 mM zVAD-fmk were treated for 6 h with 100 ng/ml CH-11 agonistic anti-Fas antibody or 1 mM
STS. The immunoblot was stained with the anti-FEATDN antibody. (f) Schematic diagram of the human FEAT structure and caspase-3 cleavage sites.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 15 | DOI: 10.1038/srep00015 2Figure 2 | FEAT is overexpressed in human cancers. (a) The immunoblot (IMB-105) contains lysates (10 mg protein/lane) from the following human
cancer-derived cell lines: HeLa, uterine cervical carcinoma; Jurkat, T-cell leukaemia; Daudi, Burkitt lymphoma; 293, embryonal kidney transformed by
adenovirus type 5; Rh 30, rhabdomyosarcoma; A375, malignant melanoma; T98G, glioblastoma; HCT-116, colon carcinoma; and Hep-2, larynx
carcinoma.ImmunofluorescencemicroscopyusingthesameantibodyrevealedthatFEATisdiffuselylocalizedinthecytoplasmandnucleusofHeLacells
(SupplementaryFig. 5;SupplementaryNote).(b)AbsenceofFEATexpressioninnormalneutrophils.Peripheralbloodmononuclearcellsfromapatient
with acute lymphoblastic leukaemia (ALL) and neutrophils from four normal volunteers were analyzed by immunoblotting. (c) FEAT attenuates
spontaneous neutrophil apoptosis. His-tagged wild-type (WT) or mutant FEAT proteins were introduced into neutrophils by protein transduction.
Apoptotic neutrophils with a hypodiploid DNA content were analyzed by flow cytometry and normalized to that of cells incubated with irrelevant
proteins(mock)(*,P50.0012,n59;**,P50.0001,n59;***,P50.0192,n54;****,P50.0135,n54;pairedt-test).Errorbars,s.e.m.(d)Multiple
Tissue Blot (Human, WB46, 75 mg protein/lane) was probed with anti-FEATDN (uppermost panel; FEAT is indicated by an arrow), anti-FEATDC
(middlepanel),andanti-actin(lowermostpanel)antibodies.(e)HumanTumorTissueBlot(WB51).Theproteinsloaded(50mg/lane)werederivedfrom
the following: ovary stromal sarcoma, lung adenocarcinoma, hepatocellular carcinoma, rectal adenocarcinoma, cervical squamous cell carcinoma, skin
malignant melanoma, testis embryonal carcinoma, thyroid follicular carcinoma, uterine adenocarcinoma, stomach adenocarcinoma, laryngopharynx
squamous cell carcinoma, breast ductal carcinoma, prostate hyperplasia, and pancreatic adenocarcinoma. (a, b, and e) Blots were probed with anti-
FEATDN (upper panels) and anti-actin (lower panels) antibodies.
www.nature.com/scientificreports
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activities.
FEAT is cleaved by caspase-3. Exogenously-expressed FEAT was
cleaved during staurosporine-induced (STS-induced) apoptosis of
COS-7 cells (Fig. 1a). In vitro transcribed/translated FEAT was
cleaved by caspase-3, but not by caspase-6 (Fig. 1b). Purified His-
tagged FEAT was cleaved by purified caspase-3. FEAT was
minimally cleaved in apoptotic MCF-7 cells, which are deficient in
caspase-3
26, and coexpression of procaspase-3 led to efficient
cleavages of FEAT (Fig. 1c). Site-directed mutagenesis studies
(Fig. 1d) revealed caspase-3 cleavage sites in human FEAT.
Endogenous FEAT was cleaved in Jurkat T cells undergoing Fas-
and STS-induced apoptosis (Fig. 1e). These results indicated that
caspase-3 cleaves FEAT in apoptotic cells (Fig. 1f). D112 and D288
are well conserved across species (Supplementary Fig. 2; Supple-
mentary Note), suggesting that caspase cleavages of FEAT play
critical role(s) in organisms.
FEAT attenuates apoptotic cell death and the antiapoptotic
activity is abrogated upon caspase-3-mediated cleavages.
Cleavages of antiapoptotic kinases and phosphatases by caspases
fine-tune apoptosis through terminating prosurvival signalling and
generating proapoptotic peptide fragments
27. We therefore assessed
whether FEAT or its caspase-3-cleaved fragments affect apoptosis.
Ex vivo experiments using plasmid transfection and RNA
interference suggested that FEAT can impede apoptosis
(Supplementary Fig. 4; Supplementary Note). We searched for cell
typesthatdonotexpressFEAT,foundthatalmostallcancer-derived
cell lines express FEAT (Fig. 2a), and decided to use neutrophils
(Fig. 2b).
Protein transduction
28 of wild-type FEAT (FEAT WT) and
FEATDN (amino acid 289–699), a fragment generated by caspase-
3 cleavage, significantly attenuated spontaneous apoptosis in neu-
trophils (Fig. 2c). The D274A/D288A mutant was more potent than
FEAT WT or FEATDN. In contrast, FEATDC (amino acid 1–274),
N-terminal fragment generated by the cleavage between the SAM-
bindingmotifs,didnotaffectapoptosis,andtheadditionofFEATDC
interfered with the antiapoptotic function of FEATDN (FEATDN 1
DC). Taken together, the results are consistent with the notion that
FEAT has the ability to attenuate apoptosis, which is abrogated by
caspase-3 cleavages between the SAM-binding motifs.
FEAT is aberrantly overexpressed in human cancer tissues. We
noticed that FEAT corresponds to the TGACCTCCAG tag that is
used in the serial analysis of gene expression (SAGE) studies of
human transcriptomes, which has been linked to a transcript that
isuniformlyelevatedinhumancolon,brain,breast,andlungcancers
and melanoma compared with the corresponding normal tissues
29.
Consistent with these classifications, immunoblotting analyses of
normal human tissues showed weak FEAT expression only in the
testis, brain, and liver (Fig. 2d), which correlated with mRNA
expression
23. In marked contrast, FEAT protein was moderately to
highly expressed in a wide range of human cancer tissues (Fig. 2e),
suggesting that FEAT is a ubiquitous protein involved in tumour
biology.
FEAT upregulation is oncogenic in vivo. To assess whether FEAT
upregulation in human cancers contributes to tumorigenesis, we
generated transgenic mice that express human FEAT under a
promoter that is active in a wide range of tissues (Supplementary
Note). Immunoblotting showed expression of FEAT in the thymus,
spleen,liver, and lung oftransgenic mice (Fig. 3a).Thymocytes from
transgenic mice showed significant decreases in Fas ligand- and
glucocorticoid-induced cell death (Fig. 3b), indicating that
transgenic expression of FEAT attenuates apoptosis.
After 12 month of age, the transgenic mice began developing
hepatocellular carcinoma (HCC), as supported by immunohisto-
chemicalanalysesofa-fetoproteinandalbumin,andmalignantlym-
phoma (Fig. 3c and Supplementary Fig. 6). HCC was also observed
in a 9-month-old male transgenic mouse (Supplementary Fig. 6),
suggesting that the hepatocarcinogenesis can be initiated earlier.
In contrast, none of the nontransgenic littermates developed HCC,
and lymphoma was observed in nontransgenic littermates with a
lower incidence (18%, 3/17). Consequently, the transgenic mice
developedtumoursordiedearlierthanthenontransgeniclittermates
(Fig. 4a). HCC and lymphoma were observed in the offspring of
four distinct founders (Fig. 3c), arguing against the possibility that
the tumorigenesis resulted from integration of the transgene in
endogenous cancer genes in the mouse genome. The murine HCC
recapitulated the strong male predilection (Fig. 3c) that is observed
in human patients
30.
Murine HCCs displayed various histological subtypes similar to
human HCCs (Fig. 4b). Lung metastases were detected in two mice
with HCC (Fig. 4c). Most lymphomas belonged to diffuse large or
Burkitt-like B-cell lymphoma (Fig. 5a), both of which expressed the
B-cell marker CD45R (B220) (100%, 15/15) (inset) and had under-
gone clonal rearrangement of the immunoglobulin genes (83%, 5/6).
These are the types of lymphoma that are most common in human
patients. None of the examined lymphomas were positive for the T-
cell marker CD3 (0%, 0/7). CD45R- and CD3-negative polymorphic
variantswithgiantcellswerealsoobserved(Fig.5b).Thelymphomas
were highly invasive and often infiltrated the pancreas (Fig. 5c).
One transgenic mouse developed both HCC and lymphoma
(Fig. 5d), and another transgenic mouse harboured three tumours,
i.e., lymphoma, HCC, and lung adenocarcinoma (Fig. 5e), as
confirmed by the expression prosurfactant protein C (insets). In
addition, one mouse had lymphoma and rhabdomyosarcoma
(Supplementary Fig. 6). Immunohistochemistry showed that
FEAT expression is higher in HCCs than adjacent liver tissues.
Sequencing analyses showed that there were no mutations in the
FEAT transgene in HCCs (0%, 0/5), suggesting that structural
changes in FEAT are not required for tumorigenesis. Unlike the
CF-1 and C3H inbred strains, the occurrence of HCC is unusual in
C57BL/6 mice
31. Thus, FEAT is a unique oncoprotein that potently
inducesbothHCCandmalignantlymphomaontheC57BL/6inbred
strain background.
FEAT transgenic mice as a relevant model for human HCCs.
Mouse models of cancers with extensive physiological and mole-
cular similarities to human patients can be exploited to determine
the causes of human cancers, to devise the strategy for cancer
prevention, and to develop and test new treatments
32. Inflam-
mation plays critical roles in the initiation and promotion of
human and murine HCCs
33. To evaluate the possibility that FEAT
promotes hepatocarcinogenesis by inducing prolonged inflam-
matory responses such as autoimmune hepatitis, we examined
whether FEAT transgenic mice with HCC have background inflam-
matory lesions in the liver. Only sparse low-grade perivasculitis with
minimal tissue destruction was observed in 50% (7/14) of the liver
adjacent to HCC in FEAT transgenic mice, while a similar degree of
perivasculitis was detected in 35% (6/17) of the liver from
nontransgenic littermates (Supplementary Fig. 7). The observa-
tions did not support the idea that FEAT causes HCC through
inflammatory mechanisms.
We next assessed whether the HCCs in FEAT transgenic mice clo-
sely model genetic events in human HCCs. The loss of p53 tumour
suppressorfunctionisakeyeventincertainsubsetsofhumanHCCs
34.
In particular, HCCs caused by aflatoxin characteristically have the
S376A mutation in p53. Mutations in the open reading frame (ORF)
ofthep53mRNAwerenotdetectedinmouseHCCs(0%,0/7).MDM2
amplification,whichisobservedinsomehumanHCCs
35,wasunlikely
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 15 | DOI: 10.1038/srep00015 4because immunohistochemistry did not reveal increased MDM2 in
the mouse HCCs compared with adjacent normal liver tissues (0%,
0/5). Activation of Wnt signalling pathway through mutations in
ß-catenin or Axin that is found in a small population of human
HCCs
36 was unlikely because of the absence of the nuclear local-
izationofß-catenin(0%,0/6)andofanymutationsinthehotspotsin
the ß -catenin gene (0%, 0/9). Overall, HCCs in the transgenic mice
do not correspond to certain minor subsets of human HCCs
36.
To evaluate whether the mouse HCCs harbour chromosomal
changes similar to human patients, the amplification (gain) or dele-
tion(loss)ofgenomicregions(copynumberalterations,CNAs)were
analyzed by microarray-based comparative genomic hybridization
(array-CGH).A genome-wideviewof large-scale CNAsshowedthat
the murine HCCs had marked genomic instability, with more gains
than losses (Supplementary Fig. 8) as observed in human HCC
37,
while the liver from a transgenic mouse without HCC had minimal
Figure 3 | Analyses of FEAT transgenic mice. (a) FEAT protein expression in nontransgenic (left panel) or transgenic (right panel) mouse organs.
Similar results were obtained with first generation offspring of three distinct founders. The blot (30 mg protein/lane) was probed with anti-FEATDN
(upper panels) and anti-actin (lower panels) antibodies. (b) Cell death of thymocytes is attenuated in FEAT transgenic mice. Survival of thymocytes
isolated from transgenic mice (Tg (1)) (red, solid lines) or nontransgenic littermates (Tg (-)) (blue, dashed lines) were analyzed by flow cytometry
(means 6 s.e.m.) after treatment for 24 h with Fas ligand (left panel) (*, P 5 0.02492; **, P 5 0.0497; ***, P 5 0.0226, n 5 5; paired t-test) or
dexamethasone (right panel) (*, P 5 0.0331; **, P 5 0.0411, n 5 6; paired t-test). (c) Tumours in founder, first and second generation FEAT transgenic
mice. HCC, hepatocellular carcinoma.
www.nature.com/scientificreports
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process of hepatocarcinogenesis rather than because of direct effects
of the FEAT transgene.
Tandem duplications that range in size from 3 kb to greater than
1Mbisthemostcommonlyobservedarchitecturesofrearrangement
inarecentstudyofhumanbreastcancergenomes
12.High-resolution
array-CGH revealed gain or loss of such small chromosomal seg-
ments in the murine HCCs. The small-scale CNAs involved 18
known cancer genes (http://www.sanger.ac.uk/genetics/CGP/
Census/) (MDS1, PDGFRA, PIK3R1, JAZF1, WHSC1L1, HOOK3,
PCM1, MLLT3, PTEN, CBL, ERCC5, ERCC4, CYLD, CBFB, BRIP1,
MLLT1, TMPRSS2, NF2) (Supplementary Table 1). TTN
4, SKP2
38,
EED1
39, and PVT1
40 have also been implicated in oncogenesis. To
directly compare the small-scale CNAs in mouse and human HCCs,
we listed focal CNAs that were shared among the murine HCCs
and identified human chromosomal loci syntenic to the CNAs
(Supplementary Table 1). The syntenic regions covered most of
thechromosomalchanges thatwerepreviously implicated inhuman
HCCs
41(Fig. 4d) and exhibited marked similarities with array-CGH
data of human HCCs
37. This cross-species synteny implies that the
carcinogenesis in these mice closely mimics that in human patients
and indicates that the FEAT transgenic mouse may be a highly
relevant model of human HCCs
42.
Molecular bases for oncogenic functions of FEAT. The oncogenic
potential of FEAT in transgenic mice seemed to be disproportionate
to the moderate ability to attenuate apoptosis (Fig. 2c, Fig. 3b, and
Supplementary Fig. 4). NIH3T3 cells that overexpressed FEAT,
FEATDN, or FEATDC did not consistently form colonies in soft
agar, suggesting that the assay for anchorage-independent growth
can fail to detect potently tumorigenic genes. This supported the
limitation of ex vivo screening for cancer genes and the much
Figure 4 | Hepatocellular carcinoma (HCC) in FEAT transgenic mice. (a) Kaplan-Meier curve for tumour-free survival of FEAT transgenic mice (Tg
(1)) (red) (n 5 40) and nontransgenic littermates (Tg (-)) (blue) (n 5 17) (P 5 0.038, log-rank test). (b) Various histological subtypes of HCC. Well-
differentiated tumours composed of dysplastic hepatocytes with atypical large polyploid nuclei and anisokaryosis with compact (upper left panel) and
trabecular(upperrightpanel)growthpatterns,andvariantssuchasaclear-celltype(leftlowerpanel)andHCCswithcytoplasmicinclusionbodies(right
lowerpanel).(c)Morphologyofneoplasticcellsinlungmetastases,whichweresimilartoprimarylivertumours.(bandc)hematoxylinandeosin(H&E)
staining. Original magnifications are: 3115 (c, left panels) and 3600 (b; c, middle and right panels). (d) Syntenic human chromosomal regions
corresponding to CNAs detected by array comparative genomic hybridization (array-CGH). Each column shows the number of genes present in each
human chromosomal arm that was commonly gained (red) or lost (green) in HCCs of FEAT transgenic mice (n 5 6). The arrows indicate the
chromosomal arms that are gained or lost in human HCCs
41.
www.nature.com/scientificreports
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mice
19.
ToevaluatewhetherFEAThascellularfunctionsrelevantinonco-
genesis, FEAT was overexpressed in NIH3T3 cells, which only
weakly express FEAT protein (Fig. 6a), and the alterations in gen-
ome-wide transcriptional profiles were analyzed by microarrays.
Gene set enrichment analysis (GSEA)
43 revealed that FEAT over-
expressionincreasesthesignaturesofreceptortyrosinekinase(RTK)
and hedgehog signalling pathways (Fig. 6b and Supplementary
Table 2), which are known to play major roles in the development
and maintenance of cancers
44–46. The results suggested that the
ability to drive multiple oncogenic pathways underlies the robust
tumorigenic potential of FEAT in vivo.
FEAT is upregulated in most human cancer cells. Previous studies
using expression microarrays reported that FEAT (KIAA0859,
CGI-01) mRNA is upregulated in uterine and ovarian cancers
(http://www.freepatentsonline.com/20050244843.html), superficial
bladder cancer (https://www.oncomine.org), adenocarcinomas of
the stomach
47, and retinoblastoma
48. To further assess the range
of human cancers in which FEAT may be involved in oncogenesis,
we examined FEAT levels in various human cancers and their
subtypes using Tissue Arrays. Immunohistochemistry detected
significant upregulation of FEAT in colon (46%, 17/37), pancreatic
(61%, 11/18), prostate (39%, 7/18), breast (51%, 18/35), ovary (24%,
6/25),thyroid(47%,9/19),andnon-small-celllungcancers(64%,14/
22) (Fig. 7 and Supplementary Fig. 9; Supplementary Table 3).
FEAT was upregulated in cancer cells but not nonneoplastic
stromal cells or normal cells adjacent to cancer tissues. Thus,
FEAT upregulation is common and widespread in human cancers,
suggesting that this phenomenon is a fundamental process in the
development of most cancers.
Notably, FEAT overexpression can also precede neoplastic trans-
formation in human HCCs; hepatocytes that were adjacent to HCC
in liver cirrhosis expressed high levels of FEAT (Fig. 8), most likely
reflecting ongoing carcinogenesis in these cirrhotic livers. FEAT
overexpression was also observed in intraductal carcinoma in situ
of breast (Supplementary Fig. 9)
49, an early phase preceding inva-
sion. These observations suggest that FEAT functions from preneo-
plastic or early neoplastic processes of diverse human cancers.
Discussion
One of the most feasible and promising approaches for cancer pre-
vention and screening is to target a common event that occurs in
most tumours. Despite these potential therapeutic advantages, it is
stillpoorlyunderstood whetheracrucial moleculareventcommonly
occurs in the early oncogenesis of most cancers. The present study
demonstrates that an unrecognized protein, FEAT, is highly onco-
genic in vivo. Remarkably, this prominent promoter of tumorigen-
esis is aberrantly overexpressed in most human cancers starting in
the early phases of tumorigenesis. Chromatin immunoprecipitation
studies with mouse embryonic stem cells (ESCs) indicate that onco-
geneproductssuchasc-Myc
50–52,N-Myc
51,andE2F1
51areboundto
the promoter of the mouse Mettl13 gene (also known as
5630401D24Rik). Amplicons in various cancers including HCC
37,
malignant lymphoma, and high-risk multiple myeloma (http://
www.freepatentsonline.com/y2008/0274911.html) involve the
Figure 5 | Lymphoma and co-occurrence of other tumours in FEAT transgenic mice. (a) Microscopic appearance of B-cell lymphomas from FEAT
transgenic mice. Centroblastic (left panel) or immunoblastic (middlepanel) variants ofdiffuse large B-celllymphoma andBurkitt-like B-cell lymphoma
with a starry sky appearance (right panel). (b) Giant cells (arrows) in polymorphic lymphoma. (c) Infiltration of lymphoma in the pancreas (arrows).
(d) A section of the lung with metastases of hepatocellular carcinoma (HCC) (rectangle, corresponding to left upper panel in Fig. 4c) and lymphoma
(inset). (e) HCC (left panel), and a lung adenocarcinoma (middle and right panels) that developed in a transgenic mouse, which also harboured
lymphoma. (a–e) H&E staining. Original magnifications are: 3600 (a), 3115 (b), 360 (c), 315 (d), and 3400 (e). The insets show
immunohistochemicalstainingforaB-cellmarkerCD45R(B220)(a),andprosurfactantproteinC,amarkeroftypeIIpneumocytes,whichwasabsentin
the HCC and present in the lung adenocarcinoma (e).
www.nature.com/scientificreports
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how FEAT protein is upregulated in tumours. Further studies are
needed to fully elucidate the regulation of FEAT expression in nor-
mal and neoplastic tissues.
FEAT was originally purified from rat livers as a protein that
inhibits nuclear apoptosis in vitro. Interestingly, FEAT homologues
werenotdetectableinunicellulareukaryotessuchasyeastsandgreen
algae (Chlamydomonas reinhardtii), suggesting that the functions of
Figure 6 | Genome-wide expression profiling of NIH3T3 cells overexpressing human FEAT. (a) Immunoblot analyses of NIH3T3 cell clones stably
transfected with a control plasmid (DccdB-1, DccdB-2, and DccdB-3) and human FEAT cDNA (FEAT-3, FEAT-15, and FEAT-20). The blot was probed
with anti-FEATDN (upper panel) and anti-actin (lower panel) antibodies. Signatures enriched in FEAT-overexpressing (FEAT-3, -15, and -20) (b) or
control (DccdB-1, -2, and -3) (c) NIH3T3 cells as assessed by gene set enrichment analysis. Enrichment plots (left panels) and heat maps (right panels)
display gene sets with enrichment score (ES) . 0.5 and false discovery rate (FDR) q-value , 0.25. RTK, receptor tyrosine kinase. GPI,
glycosylphosphatidylinositol.
www.nature.com/scientificreports
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FEAT belongs to the Myc module in mouse ESCs that is responsible
forthesimilaritybetweenESCsandcancercells
53,implicatingFEAT
as a link between cancer and stem cell biology. Ex vivo experiments
confirmed that FEATattenuates apoptotic cell death. However,gene
expression profiling revealed that FEAT also affects various cell
signalling and metabolic pathways (Fig. 6b and 6c; Supplementary
Table 2). Furthermore, in a recent genome-wide linkage analysis,
geneticvariationsinthehumanMETTL13genehavebeenassociated
with increased susceptibility to postpartum mood syndrome
54.
CpG-island microarray analyses of frontal cortex tissues have revealed
higher DNA methylation close to the METTL13 gene among bipolar
Figure 7 | Overexpression of FEAT in diverse human cancer cells. Immunohistochemical staining of Tissue Arrays using anti-FEAT DN antibody.
(a) Normal colon tissue, grade I and III adenocarcinoma of the colon. (b) Normal pancreas tissue, grade I and II adenocarcinoma of the pancreas.
(c) Normalprostate tissue, Gleasonscore1 and 3 adenocarcinomaof theprostate. (d) Normal breasttissue, infiltratingductal andlobular carcinomas of the
breast. (e) Normal thyroid tissue, grade I papillary and grade III follicular carcinomas of the thyroid. (f) Normal lung tissue, grade III adenocarcinoma and
gradeIIIsquamouscellcarcinomaofthelung.Originalmagnification:3400.ThefollowingTissueArrayswereused:Highdensitymultipleorgancancerand
normal tissue microarray, MC5001; Breast cancer tissue microarray with self-matching adjacent normal tissue and normal tissue controls, BR721; Colon
adenocarcinoma(combinationofmarginalandnormal),BC05021;andLivercarcinoma(combinationofcancer,canceradjacentandnormaltissue),LV803.
www.nature.com/scientificreports
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55. Therefore, it will be import-
ant to perform integrated studies to fully elucidate how the multifunc-
tional properties of FEAT contribute to tumorigenesis.
A potential problem with transgenic mouse models of cancer is
that the transgene is expressed throughout the entire organ, while
human cancers are thought to develop from a single mutated cell in
thecontext ofarelativelynormalorgan
32.FEATtransgenicmicedid
not have the premalignant lesions (ex. steatohepatitis, cholestatic
hepatitis, and liver fibrosis) that typically precede HCCs in other
mouse models and human patients with underlying hepatitis B or
C virus infections, alcoholic liver injury, or nonalcoholic steatohepa-
titis
41. Thus, a possible limitation of the FEAT transgenic mouse
model is that it cannot recapitulate the inflammatory mechanisms
thatunderliemosthumanHCCs.Inflammatoryresponsesleadingto
STAT3signalling downstreamofinterleukin-6havebeenimplicated
in the development of murine and human HCCs
33. Whereas FEAT
induces malignant HCCs in mice that can metastasize to the lung,
constitutive interleukin-6-STAT3 signalling can only induce benign
hepatic adenomas
56, suggesting that the inflammatory mechanisms
play central roles mainly at earlier phases in the evolution of HCCs.
Immunohistochemical analyses of Tissue Arrays from human
patientsrevealedthatFEATisdiffuselyoverexpressedinhepatocytes
in liver cirrhosis adjacent to HCC. FEAT upregulation in transgenic
mice may bypass the preneoplastic processes that precede advanced
liver cirrhosis. In compensation for the inability to recapitulate the
earlier inflammatory phases of hepatocarcinogenesis, FEAT trans-
genicmicemayhelpusinvestigatea‘pure’laterphaseofcarcinogenic
processes that are not complicated by genetic alterations that are
secondary to the preceding processes
57.
The relatively delayed development of HCC and lymphoma in
transgenic mice (Supplementary Fig. 6) implies that FEAT is
involved in promoting, rather than initiating oncogenesis. The
genomic instability that was indicated by the array-CGH also sug-
gests that multiple additional genetic alterations are required for
tumorigenesis. The incidence of tumours in transgenic mouse lines
was not correlated with differences in FEAT transgene expression
among these lines (1 . 16 . 23 ? 18), suggesting that the level of
FEAT protein is not a rate-limiting factor in tumorigenesis. In addi-
tion, Tissue Arrays showed no correlation between FEAT levels and
tumour grades. Downregulation of FEAT in human HCC compared
to the adjacent cirrhotic liver and the moderate ability of FEAT to
attenuate apoptotic cell death in HeLa cells suggested that FEAT is
not necessary to maintain cancers. Taken together, these results
indicatethatFEATupregulationpotentlypromotesthedevelopment
of multiple tumours in vivo, mainly at the prodromal and early
phases of carcinogenesis, and sets the stage for additional oncogenic
processes. Spontaneous lymphoma, HCC, lung cancer, and rhabdo-
myosarcoma can occur in C57BL/6 mice, albeit at low rates. The
occurrence of these specific types of tumours suggests that the
FEAT transgene promoted the intrinsic tendency of C57BL/6 mice
to develop tumours such as lymphoma. Therefore, it is likely that
FEAT accelerates and enhances the intrinsic predispositions of cer-
tain humans to develop cancers.
Biochemical events that are common among cancers have been
used to screen or monitor tumour development, spread, and viab-
ility, as exemplified by positron emission tomography (PET) for
glucose uptake. Compared to alterations in other oncogenes and
tumour suppressor genes
15, FEAT is upregulated in an unusually
wide range of tumours. Moreover, Tissue Array analyses dem-
onstratethatFEATupregulation canbeeasily examinedusingform-
alin-fixed paraffin-embedded sections that are available in most
community hospitals. MUC1
58 and survivin
59, which are overex-
pressedindiversecancers,arecurrentlybeingexaminedastargetsfor
immunotherapy in clinical trials. Immunization with FEAT may
trigger immune responses that eradicate precancerous lesions and
early-stagetumours,preventingfurtherdevelopmentofinvasiveand
metastatic cancers. Thus, FEAT might become the prototype of a
subfamily of cancer genes that could lead to new methods for cost-
effective cancer screening and prevention. The results of our study
suggest that we should further explore FEAT-like ubiquitous
Figure 8 | FEAT is overexpressed in liver cirrhosis adjacent to human hepatocellular carcinoma (HCC). FEAT expression in HCC and the adjacent
cirrhotic liver was compared for several patients using a Tissue Array (LV803). The age and gender (M, male) of the patients are indicated. Original
magnifications are: 3115 (leftuppermost panel,left lowermost panel), 3400 (right uppermost panel, right lowermost panel), and340 (middlepanels).
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various clinical applications.
Methods
Reagents. Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-
fmk) was obtained from Enzyme Systems. The pcDL-SRa-procaspase-3 plasmid was
kindly provided by Dr. Fumiko Toyoshima-Morimoto (Institute for Virus Research,
Kyoto University, Kyoto, Japan). The agonistic anti-Fas IgM monoclonal antibody
(CH-11) was purchased from MBL. The INSTA-Blot membrane (IMB-105) was
obtained from IMGENEX. Multiple Tissue Blot (Human) (WB46) and Human
Tumor Tissue Blot (WB51) were obtained from Calbiochem (Merck). Tissue Arrays
that were spotted with an array of formalin-fixed and paraffin-embedded specimens
derived from various normal and tumour tissues were purchased from US Biomax.
Antibodies. The following primary antibodies were used: rabbit polyclonal
antibodies against actin (A5060; Sigma), human c-Myc (Anti-Myc Tag, 06-549;
Upstate, Millipore), albumin (A0001; DakoCytomation Denmark A/S), and
prosurfactant protein C (AB3786; Chemicon International, Millipore); mouse
monoclonal antibodies against human c-Myc (9E10; sc-40), HA (Y-11; sc-805),
MDM2 (sc-965) (Santa Cruz Biotechnology), a-fetoprotein (AB3786; Vector
Laboratories), and ß-catenin (610153; BD Transduction Laboratories, BD
Biosciences).
Rabbit polyclonal antibodies against human FEATDN and human FEATDC were
produced and affinity-purified by Operon Biotechnologies (Tokyo, Japan). Detailed
characterization of the antibodies is described in Supplementary Methods.
Determination of caspase cleavage sites. The candidate aspartic acid residues
encodedbyFEATcDNAinthe pBluescript SK(-)plasmid(Stratagene)weremutated
to alanine using the GeneEditor in vitro Site-Directed Mutagenesis System
(Promega). In vitro transcription/translation of the cDNAs was performed using the
TNT T7/T3 Coupled Reticulocyte Lysate System (Promega) and Tran
35S-label (MP
Biomedicals). The [
35S]-labelled recombinant wild-type or mutant FEAT proteins
were incubated with purified recombinant caspase-3 for 2 h at 37uC, resolved by
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), and
visualized by autoradiography.
Isolation of neutrophils, protein transduction, and analysis of spontaneous
apoptosis. The PTD-4 sequence (YARAAARQARA) optimized for protein
transduction
60 was introduced between the His-tag and N-terminus of the wild-type
ormutantFEATproteins. Theproteins encodedbythepET-16bplasmids(Novagen,
Merck) were expressed in BL21(DE3)pLys Escherichia coli (Novagen, Merck) and
purified with Ni
21-NTA agarose (Qiagen) under denaturing conditions.
Neutrophils were isolated from the peripheral blood of healthy adult volunteers
using two-step Percoll (GE Healthcare Bio-Sciences) gradients. Neutrophils were
resuspended in RPMI-1640 medium (Sigma) supplemented with 10% FBS (GIBCO,
Invitrogen, Life Technologies), 50 U/ml penicillin, and 50 mg/ml streptomycin
(GIBCO, Invitrogen, Life Technologies) (FBS-RPMI) and then treated with 1 mMo f
the purified proteins for 15 min at 37uC. After the treatment, the cells were diluted
with FBS-RPMI and then incubated for 24 h at 37uC. Neutrophil apoptosis was
assessed by ethanol fixation, propidium iodide staining,and analyses ofthe cells with
hypodiploidDNAcontentusingtheFACScanflowcytometerandCellQuestsoftware
(BD Biosciences). Cell death was also confirmed by flow cytometric analyses of cells
stained with fluorescein isothiocyanate-conjugated (FITC-conjugated) annexin V
and propidium iodide using the ApoAlert annexin V Apoptosis Detection kit
(Clontech Laboratories, Takara Bio).
Generation and breeding of FEAT transgenic mice. All animal experiments were
approved by the Animal Experiment Committee at the Chiba Cancer Center.
InjectionoftheDNAfragmentcontainingtheH-2K
d(MHCClassI)promoter,FEAT
cDNA, b-globin intron, and SV40 poly (A) signal into fertilized eggs collected from
superovulated C57BL/6CrSlc females, implantation into pseudo-pregnant mice,
breeding, and weaning were performed by Japan SLC (Shizuoka, Japan).
The founder mice were screened for integration of human FEAT cDNA by
Southern blotting using genomic DNA purified from tails. Briefly, 0.5 cm of mouse
tailswereincubatedovernightat55uCin0.5 mllysisbuffer(10 mMTrisHCl,pH 7.5,
50 mMethylenediamine tetraacetic acid (EDTA), 0.5% SDS, 100 mMNaCl, and 100
mg/ml proteinase K). After adding 0.5 ml UltraPure phenol:chloroform:isoamyl
alcohol (Invitrogen, Life Technologies), the samples were rotated for 30 min at room
temperature, and then centrifuged for 2 min at 7,000 rpm. The aqueous phase was
recovered and treated similarly with 0.5 ml chloroform. The genomic DNA was
precipitated by adding 0.4 ml isopropanol, and then washed with 70% ethanol and
dissolved in 0.2 ml TE buffer (10 mM TrisHCl, pH 8.0, and 1 mM EDTA). After
digesting with BamHI and capillary transfer to Nytran SuPerCharge nylon mem-
branes using the TurboBlotter Rapid Downward Transfer Systems (Schleicher &
Schuell Bioscience, Whatman, GE Healthcare Bio-Sciences), the integrated cDNA
was detected using the AlkPhos Direct Labeling and Detection System (GE
Healthcare Bio-Sciences).
Thereafter, expression of the transgene in each mouse was determined by poly-
merasechainreaction(PCR)analysisusingDNAisolatedfromthetailbyasimplified
protocol. Briefly, 0.5 cm of tail was incubated overnight at 55uC in 100 ml lysis buffer
(20 mMTrisHCl,pH 7.5,100 mMEDTA,0.5%Tween-20(Bio-Rad),and100mg/ml
proteinase K), followed by the addition of 900 ml distilled water. For a 20 ml PCR
reaction usingKOD DashDNApolymerase(TOYOBO),0.5mlofthelysate wasused
as a template with the following primers: 59-TGGCTCTTTGGCATGGATGA-39
(forward) and 59-TATGACATCGTAGCAAGGCC-39 (reverse). Sperm were
obtained fromthe epididymides oftransgenic miceand cryopreserved byKyudo Co.,
Ltd. (Tosu, Japan).
Transgenic mice and their nontransgenic littermates were bred and maintained in
a specific pathogen-free (SPF) animal facility at the Chiba Cancer Center Research
Institute. Transgenic lines were maintained by crossing male transgenic mice to
normalfemaleC57BL/6mice(CharlesRiverLaboratories).Micethathadtumoursor
were in a moribund state were euthanized and necropsied.
Apoptotic cell death of mouse thymocytes. Thymocytes were isolated by grinding
the dissected thymus with the plunger of a 1-ml sterile syringe in FBS-RPMI at room
temperature. The cells were left untreated or treated with Fas ligand
(rhsSuperFasLigand)(Alexis)ordexamethasone(NacalaiTesque)for24 hat37uCin
a humidified atmosphere containing 5% CO2. Cell death was quantified by staining
the cells with annexin V-CFS (R&D Systems) and propidium iodide (Calbiochem,
Merck), and then analyzing the cells by flow cytometry.
Microscopic analyses of mouse tissues. After dissection, the mouse organs were
fixed with 3.7% formaldehyde in phosphate-buffered saline, sliced into 2-mm thick
sections,placedintotissuecassettes(Tissue-TekUni-Cassette;SakuraFinetekJapan),
and immersed in fresh fixative. Further processing and interpretation of the
microscopic pathology were performed by Narabyouri Research Co., Ltd. (Nara,
Japan). Briefly, fixed tissues were dehydrated through a series of ethanol (20% to
100%) and xylene solutions and embedded in paraffin using an automatic tissue
processor, sectioned with a microtome, deparaffinized, rehydrated, and stained with
hematoxylin and eosin (H&E). Immunohistochemical staining for CD45R (B220)
and CD3 was performed with an Autostainer (DAKO).
Array-CGH. The quality of genomic DNA was assessed by electrophoresis of 200 ng
DNA on a 0.8% agarose gel containing 0.5 mg/ml ethidium bromide. Only DNA
preparations without smearing were used for subsequent steps. DNA labelling and
hybridization to 244k slide format 60-mer oligonucleotide microarrays for array-
CGH (Agilent Mouse Genome CGH Microarray Kit 244A) were performed using
genomic DNA from mouse HCCs as experimental samples and genomic DNA from
the liver of a normal C57BL/6 mouse as a reference sample. The microarrays were
scanned using a Micro Array Scanner, and data were extracted using Feature
Extraction software and analyzed using CGH analytics 3.4 software according to the
manufacturer’s instructions (Agilent Technologies).
Gene expression profiling with microarrays. The ORF of human FEAT cDNA was
subcloned into the pEF-DEST51 vector (Invitrogen, Life Technologies). NIH3T3 cells
weretransfectedwithpEF-DEST51-FEATusingHilyMax(DojindoLaboratories).After
7d a y so fs e l e c t i o nw i t h1 0mg/ml blasticidin S (Kaken Pharmaceutical), colonies were
pickedandscreenedforclonesinwhichFEATproteinwasoverexpressed.TheccdBgene
in the pEF-DEST51 vector was deleted to construct the pEF-DEST51-DccdB plasmid,
which was stably transfected into NIH3T3 cells to obtain control cell lines.
Total RNA was extracted from control (DccdB-1, -2, and -3) and FEAT-overex-
pressing NIH3T3 cell lines (FEAT-3, -15, and -20) using the RNeasy Mini kit
(Qiagen). Gene expression profiling was performed with Sentrix Mouse WG-6 v2
BeadChip Array (Illumina) at the Research Support Center, Graduate School of
Medical Sciences, Kyushu University. Raw gene expression data were first subjected
to average normalization using BeadStudio 3.0 software. Average signals with
detection P-values (based on Illumina replicate gene probes) . 0.01 were removed
from analyses. GSEA was performed using the software available via the world wide
web site (http://www.broadinstitute.org/gsea/).
Immunohistochemistry. Paraffin-embedded sections were deparaffinized with
Clear-Advantage (Polysciences), rehydrated, treated with Citrate-based Antigen
Unmasking Solution (Vector Laboratories), and stained using the ImmPRESS kit
(Vector Laboratories) and ImmPACT Chromogen (Vector Laboratories) according
to the manufacturer’s instructions. The slides were counterstained with Mayer’s
Hematoxylin (Merck), and the coverslips were mounted with Gel/Mount aqueous
mounting medium (Biomeda). The stained tissues were observed by the Zeiss
Axioskop 2 plus microscope and images were acquired using the Zeiss AxioCam
camera controlled by AxioVision software (Carl Zeiss MicroImaging). Images were
also captured using the Leica MZ16 FA stereomicroscope, Leica DFC300 FX digital
camera, and Leica IM500 Image Manager software (Leica Microsystems).
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